netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Natural Compound Reduces Signs of Aging, Including Eye Dryness

RPB-supported vision researchers at Washington University School of Medicine in St. Louis have contributed key data to a new study that identifies a natural compound that slows typical signs of aging in mice. The study, published today in Cell Metabolism, shows that older mice drinking water supplemented with NMN (nicotinamide mononucleotide) resembled younger mice in measures of metabolism and energy production.

Human cells' ability to produce energy declines with age, prompting scientists to suspect that the steady loss of efficiency in the body's energy supply chain is a key driver of the aging process.

Now, scientists have shown that supplementing healthy mice with NMN—found in foods such as broccoli, avocado, cabbage, and cucumber—can compensate for this loss of energy production, reducing typical signs of aging such as gradual weight gain, loss of insulin sensitivity and declines in physical activity.

There are specific findings related to vision as well. "We demonstrated that tear production was increased after long-term NMN supplementation," said Rajendra S. Apte, MD, PhD, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences. "This may be relevant to dry eye syndrome, the prevalence of which increases significantly with aging. We also demonstrated some improvement in retinal function as measured by electrophysiology."

The study is based on the premise that NAD (another naturally occurring compound) levels decrease in multiple tissues as mice (and humans) age. But NAD was not effective when given directly to mice so the researchers at Washington University School of Medicine in St. Louis moved one step earlier in the NAD supply chain to NMN. Interestingly, younger mice did not benefit from NMN supplementation (likely due to the fact that the body naturally produces higher levels of NAD at younger ages), but as the mice aged, the supplementation significantly reduced signs of aging.

Dr. Apte notes that current research suggests that NAD+ biosynthesis is a critical process in cellular function and homeostasis in both animal models and humans. But, he notes that it will be necessary to perform well-designed clinical trials that test the safety and efficacy of high-grade NMN in humans before making the leap to using NMN (or perhaps its analogs) as pharmacotherapeutic agents.

When asked how the recent findings relate to the other research in which his lab is engaged, Dr. Apte explained, "My laboratory has a strong interest in understanding the programmatic changes that occur with aging and lead to immunosenescence [age-related deterioration of the immune system] and neurodegeneration. Understanding these molecular events will provide novel insights into eye diseases such as AMD, glaucoma and retinal degeneration."

Dr. Apte is a recipient of an RPB Physician-Scientist Award and the university's department of ophthalmology receives an unrestricted RPB grant.

To learn more about the NMN study, read the press release from Washington University in St. Louis or view the study in Cell Metabolism.

 Read the Press Release

 View the Study

Related News: Feature Story, Top Story

RPB logo

Research to Prevent Blindness Announces New Sight-Saving Vision Research Grants

RPB launches awards in data science and Diabetic Eye Disease.

Read More

 
RPB Logo

Vision Research Funding Partnership Event Takes Place Today

Leaders of organizations that fund vision research convene in Washington DC to increase collaboration and maximize the impact of research funding for sight-threatening diseases.

Read More

 
Dr. Raj Apte

Understanding Corneal Injuries in Dry Eyes

An RPB grantee makes a key discovery involving genes that are essential for eye health.

Read More

 
RPB logo

Research to Prevent Blindness Marks $400 Million in Funding to Advance Eye Disease Research

RPB funds a new round of researchers and hits a milestone in supporting vision-related breakthroughs.

Read More

 
Giving Tuesday logo

RPB Supporters Save Sight on Giving Tuesday

We welcome your generosity to help us meet our goal!

Read More

 
Dr. Palczewski and lab members

An RPB Awardee Tackles Inherited Retinal Diseases

Dr. Krzysztof Palczewski develops and applies cutting-edge gene editing techniques to challenging genetic conditions.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.